Production (Stage)
Avidity Biosciences, Inc.
RNA
$30.58
-$0.23-0.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -17.87% | 13.99% | -0.19% | 8.15% | 12.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -17.87% | 13.99% | -0.19% | 8.15% | 12.50% |
| Cost of Revenue | 60.09% | 58.98% | 41.92% | 33.42% | 23.20% |
| Gross Profit | -64.35% | -61.35% | -44.37% | -34.93% | -23.84% |
| SG&A Expenses | 89.10% | 59.14% | 52.76% | 43.86% | 35.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 66.20% | 59.01% | 44.18% | 35.56% | 25.67% |
| Operating Income | -69.78% | -60.84% | -46.20% | -36.85% | -26.30% |
| Income Before Tax | -61.46% | -51.87% | -38.69% | -30.47% | -19.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -61.46% | -51.87% | -38.69% | -30.47% | -19.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61.46% | -51.87% | -38.69% | -30.47% | -19.01% |
| EBIT | -69.78% | -60.84% | -46.20% | -36.85% | -26.30% |
| EBITDA | -70.21% | -61.10% | -46.24% | -36.75% | -26.05% |
| EPS Basic | -1.90% | 0.17% | 3.08% | 4.90% | 12.25% |
| Normalized Basic EPS | -1.90% | 0.17% | 3.08% | 4.91% | 12.26% |
| EPS Diluted | -2.02% | 0.15% | 3.06% | 4.88% | 12.24% |
| Normalized Diluted EPS | -1.90% | 0.17% | 3.08% | 4.91% | 12.26% |
| Average Basic Shares Outstanding | 58.07% | 52.76% | 44.05% | 36.52% | 33.82% |
| Average Diluted Shares Outstanding | 58.07% | 52.76% | 44.05% | 36.52% | 33.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |